Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
bromure de glycopyrronium |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Glycopyrronium adverse reaction |
Causative agent (attribute) |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Allergy to glycopyrronium |
Causative agent (attribute) |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Glycopyrronium bromide [antispasmodic] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Glycopyrronium bromide [anesthesia] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Glycopyrrolate 200micrograms/1mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Glycopyrrolate 600micrograms/3mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Glycopyrrolate 0.2mg/mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Glycopyrronium bromide 2 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Glycopyrronium bromide 1 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Product containing glycopyrronium bromide in oral dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Product containing glycopyrronium bromide in parenteral dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Glycopyrrolate 100%w/w powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Neostigmine 2.5mg/glycopyrronium 500mcg injection solution 1mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Neostigmine+glycopyrronium |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Glycopyrrolate 0.2mg/mL injection solution 1mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Glycopyrrolate 0.2mg/mL injection solution 5mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Glycopyrrolate 0.2mg/mL injection solution 20mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Glycopyrrolate 0.2mg/mL injection solution 2mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Glycopyrrolate 100%w/w powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Glycopyrronium bromide |
Is a |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Glycopyrronium bromide [anesthesia] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Glycopyrronium bromide [antispasmodic] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Glycopyrrolate 600micrograms/3mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Glycopyrrolate 200micrograms/1mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Allergy to glycopyrronium |
Causative agent (attribute) |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
1 |
Glycopyrronium bromide 2 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
1 |
Glycopyrronium bromide 2 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Glycopyrronium bromide |
Inferred relationship |
Some |
1 |
Glycopyrronium bromide 1 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
1 |
Glycopyrronium bromide 1 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Glycopyrronium bromide |
Inferred relationship |
Some |
1 |
Product containing glycopyrronium bromide and neostigmine bromide |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Product containing formoterol and glycopyrronium bromide |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Product containing glycopyrronium bromide and indacaterol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Product containing formoterol and glycopyrronium bromide in respiratory dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Product containing glycopyrronium bromide and indacaterol in respiratory dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
|
Glycopyrronium bromide 1 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Glycopyrronium bromide |
Inferred relationship |
Some |
1 |
Glycopyrronium bromide 2 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Glycopyrronium bromide |
Inferred relationship |
Some |
1 |
Product containing precisely glycopyrronium bromide 500 microgram/1 milliliter and neostigmine methylsulfate 2.5 milligram/1 milliliter conventional release solution for injection ampule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
1 |
Product containing precisely glycopyrronium bromide 500 microgram/1 milliliter and neostigmine methylsulfate 2.5 milligram/1 milliliter conventional release solution for injection ampule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
1 |
Product containing precisely glycopyrronium bromide 200 microgram/1 milliliter conventional release solution for injection ampule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
1 |
Product containing precisely glycopyrronium bromide 200 microgram/1 milliliter conventional release solution for injection ampule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
1 |
Product containing precisely glycopyrronium bromide 600 microgram/3 milliliter conventional release solution for injection ampule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
1 |
Product containing precisely glycopyrronium bromide 600 microgram/3 milliliter conventional release solution for injection ampule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
1 |
Glycopyrronium bromide 500 microgram/mL and neostigmine methylsulfate 2.5 mg/mL solution for injection |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
2 |
Glycopyrronium bromide 500 microgram/mL and neostigmine methylsulfate 2.5 mg/mL solution for injection |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Glycopyrronium bromide |
Inferred relationship |
Some |
2 |
Glycopyrronium bromide 200 microgram/mL solution for injection |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Glycopyrronium bromide |
Inferred relationship |
Some |
1 |
Glycopyrronium bromide 200 microgram/mL solution for injection |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Glycopyrronium bromide |
Inferred relationship |
Some |
1 |
Glycopyrronium bromide 500 microgram/mL and neostigmine methylsulfate 2.5 mg/mL solution for injection |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Glycopyrronium bromide |
Inferred relationship |
Some |
1 |
Glycopyrronium bromide 500 microgram/mL and neostigmine methylsulfate 2.5 mg/mL solution for injection |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Glycopyrronium bromide |
Inferred relationship |
Some |
1 |
Glycopyrronium (as glycopyrronium bromide) 320 microgram/mL oral solution |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Glycopyrronium bromide |
Inferred relationship |
Some |
1 |
Product containing precisely glycopyrronium (as glycopyrronium bromide) 160 microgram/1 milliliter conventional release oral solution (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Glycopyrronium bromide |
Inferred relationship |
Some |
1 |
Product containing precisely glycopyrronium (as glycopyrronium bromide) 44 microgram/1 actuation conventional release powder for inhalation (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Glycopyrronium bromide |
Inferred relationship |
Some |
1 |